Diabetes Metab J.  2019 Aug;43(4):383-397. 10.4093/dmj.2019.0121.

Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications

• Cappon G
• Vettoretti M
• Sparacino
• Facchinetti A

• KMID: 2455662
• DOI: http://doi.org/10.4093/dmj.2019.0121

Abstract

By providing blood glucose (BG) concentration measurements in an almost continuous-time fashion for several consecutive days, wearable minimally-invasive continuous glucose monitoring (CGM) sensors are revolutionizing diabetes management, and are becoming an increasingly adopted technology especially for diabetic individuals requiring insulin administrations. Indeed, by providing glucose real-time insights of BG dynamics and trend, and being equipped with visual and acoustic alarms for hypo- and hyperglycemia, CGM devices have been proved to improve safety and effectiveness of diabetes therapy, reduce hypoglycemia incidence and duration, and decrease glycemic variability. Furthermore, the real-time availability of BG values has been stimulating the realization of new tools to provide patients with decision support to improve insulin dosage tuning and infusion. The aim of this paper is to offer an overview of current literature and future possible developments regarding CGM technologies and applications. In particular, first, we outline the technological evolution of CGM devices through the last 20 years. Then, we discuss about the current use of CGM sensors from patients affected by diabetes, and, we report some works proving the beneficial impact provided by the adoption of CGM. Finally, we review some recent advanced applications for diabetes treatment based on CGM sensors.

Keyword

Blood glucose self-monitoring; Diabetes mellitus; Hyperglycemia; Hypoglycemia; Insulin infusion systems

MeSH Terms

Acoustics
Blood Glucose
Blood Glucose Self-Monitoring
Diabetes Mellitus
Glucose*
Humans
Hyperglycemia
Hypoglycemia
Incidence
Insulin
Insulin Infusion Systems
Blood Glucose
Glucose
Insulin

Figure

• 

  Fig. 1 (A) Representative blood glucose (BG) monitoring data obtainable with self-monitoring of blood glucose (SMBG; in green) and with continuous glucose monitoring (CGM; in blue). Dotted circles denote hyperglycemic and hypoglycemic episodes that, using only SMBG measurements, are not detectable. (B) Assessment of the accuracy of a CGM sensor can be performed by comparing Yellow Spring Instruments Inc. (YSI) measurements (red stars) versus Dexcom G4 Platinum CGM (black solid line) measurements. For example, mean absolute relative difference can be calculated as the average ratio between the absolute difference between the CGM measurements and the YSI over the YSI.

• 

  Fig. 2 Accuracy evolution of state-of-the-art CGM systems through years. From the left: Medtronic Enlite, Abbott Freestyle Navigator, Dexcom G4 Platinum, Abbott Freestyle Libre, Dexcom G4 Platinum with 505 software, Senseonics Eversense, Dexcom G5, Dexcom G6. MARD, mean absolute relative difference; SMBG, self-monitoring of blood glucose.

Reference

1. Wang J. Electrochemical glucose biosensors. Chem Rev. 2008; 108:814–825. PMID: 18154363.

2. Acciaroli G, Vettoretti M, Facchinetti A, Sparacino G. Calibration of minimally invasive continuous glucose monitoring sensors: state-of-the-art and current perspectives. Biosensors (Basel). 2018; 8:E24. PMID: 29534053.

3. Clarke SF, Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci. 2012; 69:83–93. PMID: 22872934.

4. Cappon G, Acciaroli G, Vettoretti M, Facchinetti A, Sparacino G. Wearable continuous glucose monitoring sensors: a revolution in diabetes treatment. Electronics. 2017; 6:65.

5. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008; 359:1464–1476. PMID: 18779236.

6. Battelino T, Conget I, Olsen B, Schutz-Fuhrmann I, Hommel E, Hoogma R, Schierloh U, Sulli N, Bolinder J. SWITCH Study Group. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012; 55:3155–3162. PMID: 22965294.

7. Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011; 34:795–800. PMID: 21335621.

8. Facchinetti A. Continuous glucose monitoring sensors: past, present and future algorithmic challenges. Sensors (Basel). 2016; 16:E2093. PMID: 27941663.

9. Vettoretti M, Cappon G, Acciaroli G, Facchinetti A, Sparacino G. Continuous glucose monitoring: current use in diabetes management and possible future applications. J Diabetes Sci Technol. 2018; 12:1064–1071. PMID: 29783897.

10. ISO: ISO 15197 (2013). In vitro diagnostic test systems: requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. cited 2019 Jul 15. Available from: https://www.iso.org/obp/ui/#iso:std:iso:15197:ed-2:v1:en.

11. Bailey TS. Clinical implications of accuracy measurements of continuous glucose sensors. Diabetes Technol Ther. 2017; 19:S51–S54. PMID: 28541134.

12. Zisser HC, Bailey TS, Schwartz S, Ratner RE, Wise J. Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements. J Diabetes Sci Technol. 2009; 3:1146–1154. PMID: 20144429.

13. Weinstein RL, Schwartz SL, Brazg RL, Bugler JR, Peyser TA, McGarraugh GV. Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care. 2007; 30:1125–1130. PMID: 17337488.

14. Bailey TS, Ahmann A, Brazg R, Christiansen M, Garg S, Watkins E, Welsh JB, Lee SW. Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor. Diabetes Technol Ther. 2014; 16:277–283. PMID: 24758729.

15. Geoffrey M, Brazg R, Richard W. FreeStyle Navigator Continuous Glucose Monitoring System with TRUstart algorithm, a 1-hour warm-up time. J Diabetes Sci Technol. 2011; 5:99–106. PMID: 21303631.

16. Christiansen M, Bailey T, Watkins E, Liljenquist D, Price D, Nakamura K, Boock R, Peyser T. A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. Diabetes Technol Ther. 2013; 15:881–888. PMID: 23777402.

17. Bailey TS, Chang A, Christiansen M. Clinical accuracy of a continuous glucose monitoring system with an advanced algorithm. J Diabetes Sci Technol. 2015; 9:209–214. PMID: 25370149.

18. Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015; 17:787–794. PMID: 26171659.

19. Freestyle Libre. Abbot's Freestyle Libre. cited 2019 Jul 15. Available from: https://www.freestylelibre.it/libre/.

20. Dexcom Inc.FDA authorizes marketing of the new Dexcom G6 CGM eliminating the need for fingerstick blood testing for people with diabetes. cited 2019 Jul 15. Available from: https://www.dexcom.com/news/fda-authorizes-dexcom-g6.

21. Christiansen MP, Garg SK, Brazg R, Bode BW, Bailey TS, Slover RH, Sullivan A, Huang S, Shin J, Lee SW, Kaufman FR. Accuracy of a fourth-generation subcutaneous continuous glucose sensor. Diabetes Technol Ther. 2017; 19:446–456. PMID: 28700272.

22. DexCom Inc. DexCom to collaborate with the life sciences team at Google on the development of breakthrough technologies to change the future of diabetes management. cited 2019 Jul 15. Available from: http://www.prnewswire.com/news-releases/dexcom-to-collaborate-with-the-life-sciences-teamat-google-on-the-development-of-breakthrough-technologies-to-change-the-future-of-diabetesmanagement-300126661.html.

23. Abbott. Abbott's FreeStyle Libre 2, with optional real-time alarms, secures CE mark for use in Europe. cited 2019 Jul 15. Available from: https://abbott.mediaroom.com/2018-10-01-Abbott-s-FreeStyle-R-Libre-2-with-Optional-Real-Time-Alarms-Secures-CE-Mark-for-Use-in-Europe.

24. Vaddiraju S, Burgess DJ, Tomazos I, Jain FC, Papadimitrakopoulos F. Technologies for continuous glucose monitoring: current problems and future promises. J Diabetes Sci Technol. 2010; 4:1540–1562. PMID: 21129353.

25. Chen C, Zhao XL, Li ZH, Zhu ZG, Qian SH, Flewitt AJ. Current and emerging technology for continuous glucose monitoring. Sensors (Basel). 2017; 17:E182. PMID: 28106820.

26. Dehennis A, Mortellaro MA, Ioacara S. Multisite study of an implanted continuous glucose sensor over 90 days in patients with diabetes mellitus. J Diabetes Sci Technol. 2015; 9:951–956. PMID: 26224762.

27. Gashgari H, Attallah N, Al Muallem Y, Al Dogether M, Al Moammary E, Almeshari M, Househ M. Collecting patient data from sensor-based systems: benefits and challenges. Stud Health Technol Inform. 2016; 226:41–44. PMID: 27350461.

28. Diabetes Technology Society. DTS cybersecurity standard for connected diabetes devices. cited 2019 Jul 15. Available from: https://www.diabetestechnology.org/dtsec.shtml.

29. Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care. 2015; 38:1610–1614. PMID: 26207054.

30. Longato E, Acciaroli G, Facchinetti A, Hakaste L, Tuomi T, Maran A, Sparacino G. Glycaemic variability-based classification of impaired glucose tolerance vs. type 2 diabetes using continuous glucose monitoring data. Comput Biol Med. 2018; 96:141–146. PMID: 29573667.

31. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ 3rd, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Norgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017; 40:1631–1640. PMID: 29162583.

32. International Diabetes Center. Ambulatory Glucose Profile: AGP reports. cited 2019 Jul 15. Available from: http://www.agpreport.org/agp/agpreports.

33. Aleppo G, Ruedy KJ, Riddlesworth TD, Kruger DF, Peters AL, Hirsch I, Bergenstal RM, Toschi E, Ahmann AJ, Shah VN, Rickels MR, Bode BW, Philis-Tsimikas A, Pop-Busui R, Rodriguez H, Eyth E, Bhargava A, Kollman C, Beck RW. REPLACE-BG Study Group. REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care. 2017; 40:538–545. PMID: 28209654.

34. Aleppo G, Laffel LM, Ahmann AJ, Hirsch IB, Kruger DF, Peters A, Weinstock RS, Harris DR. A practical approach to using trend arrows on the Dexcom G5 CGM system for the management of adults with diabetes. J Endocr Soc. 2017; 1:1445–1460. PMID: 29344577.

35. Pettus J, Price DA, Edelman SV. How patients with type 1 diabetes translate continuous glucose monitoring data into diabetes management decisions. Endocr Pract. 2015; 21:613–620. PMID: 25716635.

36. Cappon G, Marturano F, Vettoretti M, Facchinetti A, Sparacino G. In silico assessment of literature insulin bolus calculation methods accounting for glucose rate of change. J Diabetes Sci Technol. 2019; 13:103–110. PMID: 29848104.

37. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA. T1D Exchange Clinic Network. The T1D Exchange clinic registry. J Clin Endocrinol Metab. 2012; 97:4383–4389. PMID: 22996145.

38. Tanenbaum ML, Hanes SJ, Miller KM, Naranjo D, Bensen R, Hood KK. Diabetes device use in adults with type 1 diabetes: barriers to uptake and potential intervention targets. Diabetes Care. 2017; 40:181–187. PMID: 27899489.

39. Centers for Medicare & Medicaid Services. CGM Rulings. Ruling No. [CMS-1682-R]. cited 2019 Jul 15. Available from: www.cms.gov/Regulations-and-Guidance/Guidance/Rulings/Downloads/CMS1682R.pdf.

40. Foster NC, Miller K, Dimeglio L, Maahs DM, Tamborlane WV, Bergenstal RM, Clements MA, Rickels MR, Smith E, Olson BA, Beck R. Marked increases in CGM use has not prevented increases in HbA1c levels in participants in the T1D Exchange (T1DX) Clinic Network. Diabetes. 2018; 67(Suppl 1):1689P.

41. Abbott. Abbott FreeStyle Libre 14 day flash glucose monitoring system now approved in U.S. cited 2019 Jul 15. Available from: http://abbott.mediaroom.com/2018-07-27-Abbotts-FreeStyle-R-Libre-14-Day-Flash-Glucose-Monitoring-System-Now-Approved-in-U-S.

42. DeSalvo DJ, Miller KM, Hermann JM, Maahs DM, Hofer SE, Clements MA, Lilienthal E, Sherr JL, Tauschmann M, Holl RW. T1D Exchange and DPV Registries. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: international comparison from the T1D Exchange and DPV Initiative. Pediatr Diabetes. 2018; 19:1271–1275. PMID: 29923262.

43. Heinemann L, Stuhr A, Brown A, Freckmann G, Breton MD, Russell S, Heinemann L. Self-measurement of blood glucose and continuous glucose monitoring: is there only one future? Eur Endocrinol. 2018; 14:24–29.

44. American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes. 2019. Diabetes Care. 2019; 42(Suppl 1):S71–S80. PMID: 30559233.

45. Bailey TS, Grunberger G, Bode BW, Handelsman Y, Hirsch IB, Jovanovic L, Roberts VL, Rodbard D, Tamborlane WV, Walsh J. American Association of Clinical Endocrinologists (AACE). American College of Endocrinology (ACE). American Association of Clinical Endocrinologists and American College of Endocrinology 2016 outpatient glucose monitoring consensus statement. Endocr Pract. 2016; 22:231–261. PMID: 26848630.

46. Peters AL, Ahmann AJ, Battelino T, Evert A, Hirsch IB, Murad MH, Winter WE, Wolpert H. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016; 101:3922–3937. PMID: 27588440.

47. Jovanovic L. The role of continuous glucose monitoring in gestational diabetes mellitus. Diabetes Technol Ther. 2000; 2(Suppl 1):S67–S71. PMID: 11469635.

48. Yu F, Lv L, Liang Z, Wang Y, Wen J, Lin X, Zhou Y, Mai C, Niu J. Continuous glucose monitoring effects on maternal glycemic control and pregnancy outcomes in patients with gestational diabetes mellitus: a prospective cohort study. J Clin Endocrinol Metab. 2014; 99:4674–4682. PMID: 25057872.

49. Rodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther. 2017; 19:S25–S37. PMID: 28585879.

50. Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ, Welsh JB, Lee SW, Kaufman FR. ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013; 369:224–232. PMID: 23789889.

51. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA. STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010; 363:311–320. PMID: 20587585.

52. ClinicalTrials.gov. An evaluation of novel glucose sensing technology on hypoglycemia in type 1 diabetes (IMPACT). cited 2019 Jul 15. Available from: https://clinicaltrials.gov/ct2/show/NCT02232698.

53. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017; 8:55–73. PMID: 28000140.

54. Hermanns N, Ehrmann D, Schipfer M, Kroger J, Haak T, Kulzer B. The impact of a structured education and treatment programme (FLASH) for people with diabetes using a flash sensor-based glucose monitoring system: results of a randomized controlled trial. Diabetes Res Clin Pract. 2019; 150:111–121. PMID: 30844467.

55. Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N, Owens DR. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care. 2017; 40:832–838. PMID: 28039172.

56. Jamiolkowska M, Jamiolkowska I, Luczynski W, Tolwinska J, Bossowski A, Glowinska Olszewska B. Impact of real-time continuous glucose monitoring use on glucose variability and endothelial function in adolescents with type 1 diabetes: new technology. New possibility to decrease cardiovascular risk? J Diabetes Res. 2016; 2016:4385312. PMID: 26649320.

57. Tumminia A, Crimi S, Sciacca L, Buscema M, Frittitta L, Squatrito S, Vigneri R, Tomaselli L. Efficacy of real-time continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy: a randomized controlled crossover trial. Diabetes Metab Res Rev. 2015; 31:61–68. PMID: 24816997.

58. O'Connor PJ, Sperl-Hillen JM, Fazio CJ, Averbeck BM, Rank BH, Margolis KL. Outpatient diabetes clinical decision support: current status and future directions. Diabet Med. 2016; 33:734–741. PMID: 27194173.

59. Jia P, Zhao P, Chen J, Zhang M. Evaluation of clinical decision support systems for diabetes care: an overview of current evidence. J Eval Clin Pract. 2019; 25:66–77. PMID: 29947136.

60. Cappon G, Vettoretti M, Marturano F, Facchinetti A, Sparacino G. A neural-network-based approach to personalize insulin bolus calculation using continuous glucose monitoring. J Diabetes Sci Technol. 2018; 12:265–272. PMID: 29493356.

61. Breton MD, Patek SD, Lv D, Schertz E, Robic J, Pinnata J, Kollar L, Barnett C, Wakeman C, Oliveri M, Fabris C, Chernavvsky D, Kovatchev BP, Anderson SM. Continuous glucose monitoring and insulin informed advisory system with automated titration and dosing of insulin reduces glucose variability in type 1 diabetes mellitus. Diabetes Technol Ther. 2018; 20:531–540. PMID: 29979618.

62. DreaMed Diabeted Ltd.On DreaMed Advisor Pro. cited 2019 Jul 15. Available from: https://dreamed-diabetes.com/.

63. PR Newswire Association. DreaMed diabetes granted FDA authorization to market advisor pro, offering personalized optimization of insulin pump therapy. cited 2019 Jul 15. Available from: https://www.prnewswire.com/news-releases/dreamed-diabetes-granted-fda-authorization-to-market-advisor-pro-offering-personalized-optimization-of-insulin-pump-therapy-300667617.html.

64. Herrero P, Lopez B, Martin C. PEPPER: Patient empowerment through predictive personalized decision support. In : Proceedings of 1st Workshop on Artificial Intelligence for Diabetes (ECAI); 2016 Aug 30; Hague, NL: ECAI;2016. p. 8–9.

65. Agrawal P, Welsh JB, Kannard B, Askari S, Yang Q, Kaufman FR. Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci Technol. 2011; 5:1137–1141. PMID: 22027306.

66. Zhong A, Choudhary P, McMahon C, Agrawal P, Welsh JB, Cordero TL, Kaufman FR. Effectiveness of automated insulin management features of the MiniMed(®) 640G sensor-augmented insulin pump. Diabetes Technol Ther. 2016; 18:657–663. PMID: 27672710.

67. Buckingham BA, Cameron F, Calhoun P, Maahs DM, Wilson DM, Chase HP, Bequette BW, Lum J, Sibayan J, Beck RW, Kollman C. Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia. Diabetes Technol Ther. 2013; 15:622–627. PMID: 23883408.

68. Hughes CS, Patek SD, Breton MD, Kovatchev BP. Hypoglycemia prevention via pump attenuation and red-yellow-green “traffic” lights using continuous glucose monitoring and insulin pump data. J Diabetes Sci Technol. 2010; 4:1146–1155. PMID: 20920434.

69. Buckingham B, Chase HP, Dassau E, Cobry E, Clinton P, Gage V, Caswell K, Wilkinson J, Cameron F, Lee H, Bequette BW, Doyle FJ 3rd. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care. 2010; 33:1013–1017. PMID: 20200307.

70. Cameron F, Wilson DM, Buckingham BA, Arzumanyan H, Clinton P, Chase HP, Lum J, Maahs DM, Calhoun PM, Bequette BW. Inpatient studies of a Kalman-filter-based predictive pump shutoff algorithm. J Diabetes Sci Technol. 2012; 6:1142–1147. PMID: 23063041.

71. Abraham MB, de Bock M, Paramalingam N, O'Grady MJ, Ly TT, George C, Roy A, Spital G, Karula S, Heels K, Gebert R, Fairchild JM, King BR, Ambler GR, Cameron F, Davis EA, Jones TW. Prevention of insulin-induced hypoglycemia in type 1 diabetes with predictive low glucose management system. Diabetes Technol Ther. 2016; 18:436–443. PMID: 27148807.

72. Buckingham BA, Bailey TS, Christiansen M, Garg S, Weinzimer S, Bode B, Anderson SM, Brazg R, Ly TT, Kaufman FR. Evaluation of a predictive low-glucose management system in-clinic. Diabetes Technol Ther. 2017; 19:288–292. PMID: 28221823.

73. Choudhary P, Olsen BS, Conget I, Welsh JB, Vorrink L, Shin JJ. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther. 2016; 18:288–291. PMID: 26907513.

74. Battelino T, Nimri R, Dovc K, Phillip M, Bratina N. Prevention of hypoglycemia with predictive low glucose insulin suspension in children with type 1 diabetes: a randomized controlled trial. Diabetes Care. 2017; 40:764–770. PMID: 28351897.

75. Abraham MB, Nicholas JA, Smith GJ, Fairchild JM, King BR, Ambler GR, Cameron FJ, Davis EA, Jones TW. PLGM Study Group. Reduction in hypoglycemia with the predictive low-glucose management system: a long-term randomized controlled trial in adolescents with type 1 diabetes. Diabetes Care. 2018; 41:303–310. PMID: 29191844.

76. Vettoretti M, Facchinetti A. Combining continuous glucose monitoring and insulin pumps to automatically tune the basal insulin infusion in diabetes therapy: a review. Biomed Eng Online. 2019; 18:37. PMID: 30922295.

77. Thabit H, Hovorka R. Coming of age: the artificial pancreas for type 1 diabetes. Diabetologia. 2016; 59:1795–1805. PMID: 27364997.

78. Dadlani V, Pinsker JE, Dassau E, Kudva YC. Advances in closed-loop insulin delivery systems in patients with type 1 diabetes. Curr Diab Rep. 2018; 18:88. PMID: 30159816.

79. Bertachi A, Ramkissoon CM, Bondia J, Vehi J. Automated blood glucose control in type 1 diabetes: a review of progress and challenges. Endocrinol Diabetes Nutr. 2018; 65:172–181. PMID: 29279252.

80. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes. 2006; 55:3344–3350. PMID: 17130478.

81. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008; 31:934–939. PMID: 18252903.

82. Kropff J, Del Favero S, Place J, Toffanin C, Visentin R, Monaro M, Messori M, Di Palma F, Lanzola G, Farret A, Boscari F, Galasso S, Magni P, Avogaro A, Keith-Hynes P, Kovatchev BP, Bruttomesso D, Cobelli C, DeVries JH, Renard E, Magni L. AP@home consortium. 2 Month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol. 2015; 3:939–947. PMID: 26432775.

83. Atlas E, Nimri R, Miller S, Grunberg EA, Phillip M. MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care. 2010; 33:1072–1076. PMID: 20150292.

84. Stone MP, Agrawal P, Chen X, Liu M, Shin J, Cordero TL, Kaufman FR. Retrospective analysis of 3-month real-world glucose data after the MiniMed 670G system commercial launch. Diabetes Technol Ther. 2018; 20:689–692. PMID: 30160523.

85. Cameron FM, Ly TT, Buckingham BA, Maahs DM, Forlenza GP, Levy CJ, Lam D, Clinton P, Messer LH, Westfall E, Levister C, Xie YY, Baysal N, Howsmon D, Patek SD, Bequette BW. Closed-loop control without meal announcement in type 1 diabetes. Diabetes Technol Ther. 2017; 19:527–532. PMID: 28767276.

86. Boughton CK, Bally L, Martignoni F, Hartnell S, Herzig D, Vogt A, Wertli MM, Wilinska ME, Evans ML, Coll AP, Stettler C, Hovorka R. Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2019; 7:368–377. PMID: 30935872.

87. Bally L, Thabit H, Hartnell S, Andereggen E, Ruan Y, Wilinska ME, Evans ML, Wertli MM, Coll AP, Stettler C, Hovorka R. Closed-loop insulin delivery for glycemic control in noncritical care. N Engl J Med. 2018; 379:547–556. PMID: 29940126.

88. Taleb N, Carpentier AC, Messier V, Ladouceur M, Haidar A, Rabasa-Lhoret R. Efficacy of artificial pancreas use in patients with type 2 diabetes using intensive insulin therapy: a randomized crossover pilot trial. Diabetes Care. 2019; 42:e107–e109. PMID: 31221705.

89. Peters TM, Haidar A. Dual-hormone artificial pancreas: benefits and limitations compared with single-hormone systems. Diabet Med. 2018; 35:450–459. PMID: 29337384.

90. Lewis D, Leibrand S. #OpenAPS Community. OpenAPS Community. Real-world use of open source artificial pancreas systems. J Diabetes Sci Technol. 2016; 10:1411. PMID: 27510442.

91. Litchman ML, Lewis D, Kelly LA, Gee PM. Twitter analysis of #OpenAPS DIY artificial pancreas technology use suggests improved A1C and quality of life. J Diabetes Sci Technol. 2019; 13:164–170. PMID: 30198751.

92. Medtronic. Medtronic and Qualcomm collaborate to aim to improve care and health outcomes for people with type 2 diabetes. cited 2019 Jul 15. Available from: http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irolnewsArticle&ID=2172203.

93. SugarBEAT®. SugarBEAT 2017. cited 2019 Jul 15. Available from: http://sugarbeat.com.

94. LifePlus. LifePlus Inc;cited 2019 Jul 15. Available from: https://www.lifeplusinc.net.

95. U.S. Food & Drug Administration. FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices. cited 2019 Jul 15. Available from: https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-fully-interoperable-continuous-glucose-monitoring-system-streamlines-review.

96. Stenerson M, Cameron F, Wilson DM, Harris B, Payne S, Bequette BW, Buckingham BA. The impact of accelerometer and heart rate data on hypoglycemia mitigation in type 1 diabetes. J Diabetes Sci Technol. 2014; 8:64–69. PMID: 24876539.

97. DeBoer MD, Chernavvsky DR, Topchyan K, Kovatchev BP, Francis GL, Breton MD. Heart rate informed artificial pancreas system enhances glycemic control during exercise in adolescents with T1D. Pediatr Diabetes. 2017; 18:540–546. PMID: 27734563.